Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;7(5):518-522.
doi: 10.1016/j.jaccao.2025.05.014.

Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form Primer

Rudolf A de Boer  1 , Laura I Yousif  2 , Joseph Pierre Aboumsallem  2 , Wouter C Meijers  2
Affiliations
Review

Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form Primer

Rudolf A de Boer et al. JACC CardioOncol. 2025 Aug.
No abstract available

Keywords: cancer; cardiovascular disease; heart failure; mechanisms; reverse cardio-oncology; risk factor; underlying mechanisms.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr de Boer is supported by the Netherlands Heart Foundation (grants 2020B005 and 01-003-2022-0358), a Netherlands Heart Foundation grant cofunded by ERA4Health (GA grant 101095426 of the European Union Horizon Europe Research and Innovation Programme), and the European Research Council (CoG 818715). Dr Meijers is supported by grants from the Dutch Heart Foundation (Dekkerbeurs 03-005-2021-T005) and ZonMw (Off Road [04510012210034] and NWO-VENI [09150162310159]). The institution of Dr de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol Myers Squibb, Novo Nordisk, and Roche. Dr de Boer has had speaker engagements with, received fees from, and/or served on advisory boards for Abbott, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Roche, and Zoll; and has received travel support from Abbott and Novo Nordisk. Dr Meijers has received speaker and advisory board fees from Daiichi-Sankyo and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Crosstalk Between HF and Cancer Throughout the Spectrum The relationship between heart failure (HF) and cancer is being investigated in each phase of the spectrum; clinical insights suggest that patients with HF might be more at risk of developing specific cancers and that HF treatment might be beneficial; during incident HF, there are multiple pathophysiological mechanisms that can drive tumor growth (eg, secreted proteins, the gut microbiome), and certain clinical manifestations of progressed HF can unmask the presence of already existing cancer (eg, hypercoagulability, certain biomarkers). GRMT = guideline-recommended medical therapy.
See this image and copyright information in PMC

References

    1. Koop Y., Yousif L., de Boer R.A., Bots M.L., Meijers W.C., Vaartjes I. Dutch cardio-oncology cohort: incident cardiovascular disease predisposes to a higher cancer mortality rate. Eur J Clin Invest. 2024;54
    1. de Boer R.A., Aboumsallem J.P., Bracun V., et al. A new classification of cardio-oncology syndromes. Cardio-Oncology. 2021;7(1):24. - PMC - PubMed
    1. Mirabel M., Nevoret C., Domengé O., et al. Increased cancer incidence in patients with pre-existing heart failure: results from a French nationwide cohort study. Eur J Prev Cardiol. Published online March 20, 2025 doi: 10.1093/eurjpc/zwaf152. - DOI
    1. Sayour N.V., Paál Á.M., Ameri P., et al. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. Eur Heart J. 2024;45:1224–1240. - PMC - PubMed
    1. Dabour M.S., George M.Y., Daniel M.R., Blaes A.H., Zordoky B.N. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6:159–182. - PMC - PubMed